BCRX
NASDAQBioCryst Pharmaceuticals Inc.
Price$9.29+0.27 (+2.99%)
01:30 PM07:45 PM
News · 26 weeks64-71%
2026-01-182026-07-12
Mix3690d
- Insider16(44%)
- Other9(25%)
- SEC Filings8(22%)
- Earnings1(3%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- PRBioCryst Appoints David W. Jenkins as Chief Scientific OfficerRESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company’s Boston office. Dr. Jenkins has spent over 20 years working in the biopharmaceutic
- ANALYSTAnalyst resumed coverage on BioCryst Pharma with a new price targetAnalyst resumed coverage of BioCryst Pharma with a rating of Neutral and set a new price target of $12.00
- PRBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock. The options and RSUs were granted as of July 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.65 per share, which is equal to the closing price of B
- SECBioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
- PRBioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth— —Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal HAE study to date— —Resolves previously disclosed manufacturing delay of ORLADEYO® (berotralstat) oral pellets; product to be available in early August— —Improves 2026 non-GAAP operating expense guidance from $450-$470 million to $420-$440 million and reaffirms revenue guidance— RESEARCH TRIANGLE PARK, N.C., June 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today announced that, as part of the Company’s ongoing stra
- INSIDERDirector Milne Jill C. was granted 15,294 shares, increasing direct ownership by 92% to 31,938 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Galson Steven K was granted 15,294 shares, increasing direct ownership by 122% to 27,794 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Levin Alan G was granted 15,294 shares, increasing direct ownership by 24% to 79,565 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Frank Steven was granted 15,294 shares, increasing direct ownership by 76% to 35,459 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Sanders Machelle was granted 15,294 shares, increasing direct ownership by 50% to 45,936 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Milano Vincent was granted 15,294 shares, increasing direct ownership by 16% to 108,483 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Stonehouse Jon P was granted 15,294 shares, increasing direct ownership by 1% to 1,339,775 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Mckee Amy E was granted 15,294 shares, increasing direct ownership by 48% to 47,177 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Heggie Theresa was granted 15,294 shares, increasing direct ownership by 23% to 80,646 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- SECBioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)
- PRBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.57 per share, which is equal to the closing price of B
- INSIDERDirector Milne Jill C. was granted 1,262 shares, increasing direct ownership by 8% to 16,644 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Stonehouse Jon P was granted 631 shares, increasing direct ownership by 0.05% to 1,324,481 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Mckee Amy E was granted 631 shares, increasing direct ownership by 2% to 31,883 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Milano Vincent was granted 1,122 shares, increasing direct ownership by 1% to 93,189 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERDirector Frank Steven was granted 1,262 shares, increasing direct ownership by 7% to 20,165 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- PRBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingRESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026. Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes with navenibart, a long-acting, monoclonal antibody plasma kallikrein inhib
- INSIDERDirector Mckee Amy E sold $100,285 worth of shares (11,180 units at $8.97), decreasing direct ownership by 26% to 31,252 units (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- INSIDERChief Legal Officer Barnes Alane P exercised 62,500 shares at a strike of $5.04 and sold $596,250 worth of shares (62,500 units at $9.54) as part of a pre-agreed trading plan (SEC Form 4)4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)
- SECSEC Form 144 filed by BioCryst Pharmaceuticals Inc.144 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)
BCRX FAQ
7 questionsWhat does BioCryst Pharmaceuticals Inc. do?
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an...Where does BCRX stock trade?
BioCryst Pharmaceuticals Inc. (BCRX) is listed on NASDAQ.What sector and industry is BCRX in?
BioCryst Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did BioCryst Pharmaceuticals Inc. go public?
BioCryst Pharmaceuticals Inc. (BCRX) completed its IPO in 1994.What are analysts saying about BCRX?
BioCryst Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Neutral with a $1200.00 price target on 2026-07-13. Recent price targets range from $800.00 to $3000.00.What companies are similar to BCRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare BCRX side-by-side with any of them on Quantisnow.How can I track BCRX on Quantisnow?
Quantisnow aggregates BioCryst Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCRX to receive live email and push alerts on every new disclosure.